Recent Clinical Experience with Oncolytic Viruses
O. G. Donnelly, F. Errington-Mais, R. Prestwich, K. Harrington, H. Pandha, R. Vile and A. A. Melcher
Affiliation: Leeds Institute of Molecular Medicine, St James’s University Hospital, Beckett Street, Leeds, UK, LS9 7TF.
Keywords: Oncolytic virus, adenovirus, measles, reovirus, vaccinia, cancer, replication-competent viruses
There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by
significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published
clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia)
have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach.
Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.
Rights & PermissionsPrintExport